Equities

Panion & BF Biotech Inc

1760:TAI

Panion & BF Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)89.60
  • Today's Change0.10 / 0.11%
  • Shares traded78.20k
  • 1 Year change-19.64%
  • Beta--
Data delayed at least 20 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Oct-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform0
Hold2
Sell0
Strong Sell0

Share price forecast in TWD

The one analyst offering a 12 month price target expects Panion & BF Biotech Inc share price to rise to 107.50 in the next year from the last price of 89.60.
High20.0%107.50
Med20.0%107.50
Low20.0%107.50

Earnings history & estimates in TWD

On Nov 12, 2024, Panion & BF Biotech Inc reported 3rd quarter 2024 earnings of 0.32 per share.
The next earnings announcement is expected on Mar 05, 2025.
Average growth rate+58.53%
Panion & BF Biotech Inc reported annual 2023 earnings of 0.90 per share on Mar 07, 2024.
Average growth rate+48.27%
More ▼

Revenue history & estimates in TWD

Panion & Bf Biotech Inc. had 3rd quarter 2024 revenues of 501.21m. This missed the 511.00m consensus estimate of the 2 analysts following the company. This was 22.69% above the prior year's 3rd quarter results.
Average growth rate+1.78%
Panion & Bf Biotech Inc. had revenues for the full year 2023 of 1.88bn. This was 21.54% below the prior year's results.
Average growth rate+6.37%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.